Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02526173 · ClinicalTrials.gov registry record · NA

DHACM in Robotic Assisted Laparoscopic Prostatectomy (RALP)

A NA study, sponsored by MiMedx Group.

Completed
Registry status
NA
Development phase
230
Enrollment target

NCT02526173: Completed NA study, sponsored by MiMedx Group.

NCT02526173 is a NA study that has completed, run by MiMedx Group. The registered enrollment target is 230 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02526173, a NA study, has completed, sponsored by MiMedx Group.

COMPLETED
Registry status
NA
Development phase
230 participants
Enrollment target

Study Summary

The investigators will examine the beneficial impacts of applying of dHACM on the preserved neurovascular bundles (cavernosal nerves) and the prostate bed during robotic assisted laparoscopic prostatectomy. Such application can result in promotion of soft tissue healing and reduction of inflammation at the operative site and thus an acceleration of return of potency regulating cavernosal nerves.

Primary Outcome

As measured by SHIM

Interventions

  • PROCEDURE RALP using full nerve sparing technique
  • OTHER dHACM Application

Trial Details

FieldValue
Enrollment Target 230 participants
Start Date 2015-10-01
Est. Completion 2018-06-21
Phase NA
MiMedx Group

32 total trials

What the finished NCT02526173 record still lists

NCT02526173 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (84% lower).

The record links to 0 conditions, and to 2 interventions - of which RALP using full nerve sparing technique is the first listed.

NCT02526173 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02526173 about?

NCT02526173 is a clinical study titled "DHACM in Robotic Assisted Laparoscopic Prostatectomy (RALP)". The investigators will examine the beneficial impacts of applying of dHACM on the preserved neurovascular bundles (cavernosal nerves) and the prostate bed during robotic assisted laparoscopic prostatectomy. Such application can result in promotion of soft tissue healing and reduction of inflammation...

What is the current status of trial NCT02526173?

This trial is currently completed. It is a NA study. The enrollment target is 230 participants. The study started on 2015-10-01. Estimated completion is 2018-06-21.

What interventions are being tested in trial NCT02526173?

The interventions under investigation include: RALP using full nerve sparing technique (PROCEDURE), dHACM Application (OTHER).

Who is sponsoring clinical trial NCT02526173?

This trial is sponsored by MiMedx Group, which has 32 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02526173's enrollment target sits among peer trials

230 465th of 2000 higher than 1,533 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02710253 · 230 participants · Phase 2

    Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

  • NCT02777879 · 230 participants

    Lung Microbiome and Inflammation in Early COPD

  • NCT03824483 · 230 participants · Phase 2

    Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

  • NCT03833622 · 230 participants · NA

    Shared Decision Making to Improve Goals of Care in the ED

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02526173, the US trial registry maintained by the National Library of Medicine. NCT02526173 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.